|Event Title||First Global Alliance for Research on Avian Diseases (GARAD) Conference|
|Event Date & Time||On Tue, 30 Jun 2015 at 11:35:00 - 11:50:00|
|Venue||Edmond J. Safra Lecture Theatre|
|Abstract Title||Safety and efficacy of INNOVAX-ILT, a turkey herpesvirus recombinant vaccine expressing infectious laryngotracheitis genes|
|Authors||Gerdy. B. ten Dam|
|Affiliations||Global Poultry R&D, MSD Animal Health, Wim de Körverstraat 35, 5831 AN, Boxmeer, The Netherlands|
Infectious laryngotracheitis (ILT) is an acute viral infection in chickens associated with acute respiratory disease that may lead to severe production losses due to mortality and/or decreased egg production. Vaccination with live attenuated ILT virus (ILTV) vaccine of chicken embryo origin (CEO) or tissue culture origin (TCO) has been proven efficacious in controlling ILT but these vaccines can result in latently infected carriers birds and spread of the vaccine to non-vaccinates may occur. This may result in virus with higher levels of virulence and outbreaks of (vaccine) ILT virus in the field.
MSD Animal Health developed a herpesvirus of turkeys (HVT) recombinant vaccine (INNOVAX-ILT) expressing the glycoproteins D (gD) and I (gI) of ILTV. This vaccine is safe as shown in lab safety studies when administered to one day old SPF birds but also in the field as no adverse reactions have been observed during the rearing and production period and no influence on egg production was observed. The INNOVAX-ILT vaccine is efficacious when administered via the subcutaneous route to one day old birds as it provides protection against both Marek’s disease and ILT. It can be administered simultaneously with Nobilis Rismavac and concurrently with Nobilis ND Clone 30 or Nobilis ND C2 and with Nobilis IB Ma5 or Nobilis IB 4/91 which are given via the ocular route at one day of age.